Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

83%

5 of 6 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 2

4(50.0%)

Phase 1

4(50.0%)

8Total

Phase 2(4)

Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06592586Phase 2Active Not Recruiting

A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women

Role: lead

NCT06280157Terminated

A Follow up Study of Group B Streptococcus (GBS)-NN/NN2 Vaccine in Healthy Volunteers

Role: lead

NCT05782179Phase 1Completed

Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly Participants

Role: lead

NCT05154578Phase 2Completed

Immunogenicity and Safety of GBS-NN/NN2 in Pregnant Women

Role: lead

NCT05005247Phase 1Completed

Study to Assess a Booster Dose of GBS-NN/NN2 Vaccine

Role: lead

NCT06494475Phase 2Not Yet Recruiting

GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of Age

Role: lead

NCT04596878Phase 2Completed

Study of a Group B Streptococcus Vaccine in Pregnant Women Living With HIV and in Pregnant Women Who do Not Have HIV

Role: lead

NCT03807245Phase 1Completed

Group B Streptococcus Vaccine in Healthy Females

Role: lead

NCT02459262Phase 1Completed

Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non-pregnant Women 18-40 Years of Age.

Role: lead

All 9 trials loaded